Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-6


Brief Information

Target Synonym:CTL Differentiation Factor,Interleukin 6 (Interferon, Beta 2),HSF,B-cell stimulatory factor 2,Interferon beta-2,IL6,IFNB2,IL-6,Interleukin-6,Interleukin 6,Hybridoma Growth Factor,IFN-Beta-2,BSF-2,CDF,B-Cell Differentiation Factor,Interferon, Beta 2,Interleukin BSF-2,BSF2,HGF
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GMP-L06H27-Cell-based assay

GMP Human IL-6 Protein (Cat. No. GMP-L06H27) stimulates proliferation of TF-1 human erythroleukemic cell line. The specific activity of GMP Human IL-6 Protein is > 1.00×10^8 IU/mg, which is calibrated against human IL-6 WHO International Standard (NIBSC code: 21/308) (QC tested).

IL6-H8218-Cell-based assay

Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).


Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Immobilized Cynomolgus IL-6, His Tag (Cat. No. IL6-C5249) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha, Fc,Avitag (Cat. No. ILR-H82F9) with a linear range of 0.6-39 ng/mL (QC tested).

Synonym Name



Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and  IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells, to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor  and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Lenalidomide IMID-5013; CDC-5013; CDC-501; CC-5013; IMiD-3; ENMD-0997; STAR-LLD Approved Celgene Corp Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo United States Myelodysplastic Syndromes Bristol Myers Squibb Srlcompany 2005-12-27 Lymphoma, T-Cell, Peripheral; Optic Nerve Glioma; Intestinal Neoplasms; Immunoproliferative Small Intestinal Disease; Solid tumours; Bone Marrow Neoplasms; Lymphoma, B-Cell, Marginal Zone; Kidney Neoplasms; Leukemia; Liver Neoplasms; Hematologic Diseases; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Ependymoma; HIV Infections; Ovarian Neoplasms; Medulloblastoma; Leukemia, Hairy Cell; Anemia; Paraproteinemias; Pain; Polycythemia Vera; Plaque, Amyloid; Rhabdoid Tumor; Anemia, Refractory, with Excess of Blasts; Glioblastoma; Smoldering Multiple Myeloma; Anemia, Refractory; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Myelodysplastic Syndromes; Hypothalamic Neoplasms; Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Plasmacytoma; Blood Protein Disorders; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Acute; Nerve Degeneration; Lymphomatoid Granulomatosis; Pancreatic Neoplasms; Multiple Myeloma; Leukemia, Megakaryoblastic, Acute; Oligodend Details
Luminol sodium MP-1032 Approved Selvim, Metrio Immune System Diseases; Psoriasis null 1997-01-01 Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis Details
Pomalidomide IMID-4047; CDC-394; CC-4047; IMiD-1 Approved Celgene Corp Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 United States Multiple Myeloma Bristol-Myers Squibb Company 2013-02-08 Pulmonary Fibrosis; Atypical Squamous Cells of the Cervix; Sarcoma, Kaposi; Anemia, Sickle Cell; Neurofibromatosis 1; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Waldenstrom Macroglobulinemia; Glioma; Primary Myelofibrosis; Sarcoma; Thrombocytosis; Prostatic Neoplasms; Lung Diseases, Interstitial; Medulloblastoma; Central Nervous System Neoplasms; Multiple Myeloma; Hodgkin Disease; Plasmacytoma; Kidney Diseases; Pancreatic Neoplasms; Immunoglobulin Light-chain Amyloidosis; Myeloproliferative Disorders; Graft vs Host Disease; Scleroderma, Systemic; Polycythemia Vera; Bone Marrow Neoplasms; Solid tumours Details
Siltuximab cCLB-8; CNTO-328 Approved Johnson & Johnson Sylvant United States Multicentric Castleman's Disease (MCD) Janssen Biotech Inc 2014-04-23 Psychotic Disorders; Leukemia, Large Granular Lymphocytic; Lymphoma, Non-Hodgkin; Lung Neoplasms; Thrombocytopenia; Colorectal Neoplasms; Castleman Disease; Primary Myelofibrosis; Prostatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Multicentric Castleman's Disease (MCD); Lung Diseases; Monoclonal Gammopathy of Undetermined Significance; Respiratory Distress Syndrome, Adult; Multiple Myeloma; Bone Marrow Neoplasms; Immunoglobulin Light-chain Amyloidosis; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Respiratory Tract Diseases; Schizophrenia; Pneumonia; Carcinoma, Renal Cell; Polycythemia Vera; Kidney Neoplasms; Respiratory Tract Infections; Cytokine Release Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1 Details
Andrographolide/Sodium Hydrogen Sulfite Approved Bacterial Infections Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Mainland China Leprosy, Lepromatous; Multiple Myeloma Changzhou Pharmaceutical Factory 1982-01-01 HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ensereptide PXL-01 Phase 3 Clinical Promore Pharma Post-surgical adhesions; Tissue Adhesions; Cicatrix Details
Olokizumab CDP-6038; Anti-IL6-UCB Phase 3 Clinical Ucb Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis; Crohn Disease Details
Efprezimod alfa CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 Phase 3 Clinical Oncoimmune Inc Solid tumours; Hematopoietic stem cell transplantation (HSCT); Leukemia; HIV Infections; Graft vs Host Disease; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma Details
Ziltivekimab COR-001 Phase 3 Clinical Astrazeneca Plc Myocardial Infarction; Heart Failure; Anemia; Atherosclerosis; Cardiovascular Diseases; Inflammation; Renal Insufficiency, Chronic; Systemic Inflammatory Response Syndrome Details
Clazakizumab ALD-518; ALD518-003; BMS-645429; BMS-945429 Phase 3 Clinical Alder Biopharmaceuticals Plaque, Atherosclerotic; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Kidney Failure, Chronic; Stomatitis Details
RO-7200220 RO-7200220 Phase 3 Clinical F. Hoffmann-La Roche Ltd Macular Edema; Diabetic macular oedema Details
PF-04236921 PF-4236921; PF-04236921; TOUR006; TOUR-006 Phase 2 Clinical Pfizer Inc Arthritis, Rheumatoid; Graves Ophthalmopathy; Lupus Erythematosus, Systemic; Renal Insufficiency, Chronic; Crohn Disease Details
Sirukumab BA-003; CNTO-136 Phase 2 Clinical Glaxosmithkline Plc, Johnson & Johnson Innovative Medicine Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma Details
KSI-501 KSI-501 Phase 2 Clinical Kodiak Sciences Inc Retinal Diseases; Wet Macular Degeneration; Diabetic macular oedema; Uveitis Details
Anti-interleukin-6 receptor monoclonal antibody (Biocad) Phase 2 Clinical Biocad Autoimmune Diseases Details
Isomyosamine MYMD-1 Phase 2 Clinical Mymd Pharmaceuticals Inc Depression; Anxiety; Hashimoto Disease; Frailty; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia Details
FB-704A FB-704; FB-704A Phase 2 Clinical Fountain Biopharma Inc Arthritis, Rheumatoid; Asthma Details
Gerilimzumab GB-224; RYI-008; ARGX-109 Phase 1 Clinical Argenx Se Arthritis, Rheumatoid Details
RG-6179 RG-6179 Phase 1 Clinical F. Hoffmann-La Roche Ltd Diabetic macular oedema Details
MEDI-5117 WBP-216; MEDI-5117 Phase 1 Clinical Wuxi Apptec Co Ltd, Medimmune Arthritis, Rheumatoid Details
Tocilizumab biosimilar (Mycenax Biotech) Phase 1 Clinical Mycenax Biotech Inc Arthritis, Rheumatoid Details
NEX-20A NEX-20A Phase 1 Clinical Nanexa AB Multiple Myeloma Details
Wogonin Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message